ATOSSA THERAPEUTICS, INC. Impairment of Intangible Assets, Finite-lived
ATOSSA THERAPEUTICS, INC. (ATOS) reported Impairment of Intangible Assets, Finite-lived of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2022-02-28
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets, finite-lived for the quarter ending 2016-12-31 was $126.67K.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets, finite-lived for the quarter ending 2016-09-30 was $0.00.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets, finite-lived for the quarter ending 2016-06-30 was $0.00.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets, finite-lived for the quarter ending 2016-03-31 was $36.67K.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets, finite-lived for fiscal 2021 was $0.00.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets, finite-lived for fiscal 2020 was $0.00.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets, finite-lived for fiscal 2019 was $0.00.
- ATOSSA THERAPEUTICS, INC. impairment of intangible assets, finite-lived for fiscal 2016 was $163.33K.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-31 | |||
| 2016-12-31 | $126.67K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2017-03-21 | $126.67K derived: sum of 2 quarters · filed 2017-03-21 | $126.67K derived: sum of 3 quarters · filed 2017-03-21 | $163.33K 10-K/A · filed 2017-03-21 |
| 2016-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-03-21 | $0.00 derived: sum of 2 quarters · filed 2017-03-21 | $36.67K 10-Q/A · filed 2017-03-21 | |
| 2016-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-03-21 | $36.67K 10-Q/A · filed 2017-03-21 | ||
| 2016-03-31 | $36.67K 10-Q/A · filed 2017-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |